期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 40, 期 12, 页码 1006-1020出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2019.10.007
关键词
-
资金
- National Institutes of Health (NIH) [F31 MH114368, T32 MH64913]
- Canadian Institutes of Health Research (CIHR) [DFS146189]
- Vanderbilt International Scholars Program
- NIH [R01 MH073676]
Muscarinic acetylcholine receptors (mAChR) play important roles in regulating complex behaviors such as cognition, movement, and reward, making them ideally situated as potential drug targets for the treatment of several brain disorders. Recent advances in the discovery of subtype-selective allosteric modulators for mAChRs has provided an unprecedented opportunity for highly specific modulation of signaling by individual mAChR subtypes in the brain Recently, mAChR allosteric modulators have entered clinical development for Alzheimer's disease (AD) and schizophrenia, and have potential utility for other brain disorders. However, mAChR allosteric modulators can display a diverse array of pharmacological properties, and a more nuanced understanding of the mAChR will be necessary to best translate predinical findings into successful clinical treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据